### FORWARDHEALTH

## PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR PSORIASIS

**Instructions:** Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Psoriasis Instructions, F-11306A. Providers may refer to the Forms page of the ForwardHealth Portal at <u>www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage</u> for the completion instructions.

Pharmacy providers are required to have a completed PA/PDL for Cytokine and CAM Antagonist Drugs for Psoriasis form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

| SECTION I – MEMBER INFORMATION                                 |                           |  |
|--|---------------------------|--|
| 1. Name – Member (Last, First, Middle Initial)                 |                           |  |
|  |                           |  |
| 2. Member ID Number  | 3. Date of Birth – Member |  |
|  |                           |  |
| SECTION II – PRESCRIPTION INFORMATION                          |                           |  |
| 4. Drug Name   | 5. Drug Strength          |  |
|  |                           |  |
| 6. Date Prescription Written                                   | 7. Directions for Use     |  |
|  |                           |  |
| 8. Name – Prescriber   | _                         | 9. National Provider Identifier (NPI) – Prescriber |
|  |                           |  |
| 10. Address – Prescriber (Street, City, State, ZIP+4 Code)     |                           |  |
|  |                           |  |
| 11. Telephone Number – Prescriber                              |                           |  |
|  |                           |  |
| SECTION III – CLINICAL INFORMATION FOR PSORIASIS               |                           |  |
| 12. Diagnosis Code and Description                             |                           |  |
|  |                           |  |
| 13. Does the member have psoriasis?                            |                           | 🛛 Yes 🔲 No   |
|  |                           |  |
| If yes, indicate the areas affected and the approximate percen | t of body surfac          | ce area involved.                                  |
|  |                           |  |
|  |                           |  |
|  |                           |  |
|  |                           |  |

14. Is the prescription written by a dermatologist or through a dermatology consultation?



DT-PA074-074

Yes

No

Continued

| SECTION III – CLINICAL INFORMATION FOR PSORIASIS (Continued)   |            |     |    |
|--|------------|-----|----|
| 15. Is the member currently using the requested cytokine and CAM antagonist drug?  | <b>.</b> . | Yes | No |
| If yes, indicate the approximate date therapy was started.   |            |     |    |
|  |            |     |    |
| 16. Has the member attempted any of the following drugs or therapies for<br>psoriasis: cyclosporine, methotrexate, phototherapy, or acitretin? |            | Yes | No |

If yes, indicate the drug or therapy name(s), dose, specific details about the treatment response, and the approximate dates each drug was taken in the space provided. If additional space is needed, continue documentation in Section VI of this form.

17. Has the member attempted other drugs for psoriasis Yes No (e.g., topicals, glucocorticoids, or IV immunomodulators such as infliximab)?

If yes, indicate the drug name(s), dose, specific details about the treatment response, and the approximate dates each drug was taken in the space provided. If more space is needed, continue documentation in Section VI of this form.

| SECTION III A – ADDITIONAL CLINICAL INFORMATION FOR NON-PREFERRED CYTOKINE AND CAM ANTAGONIST DRUG REQUESTS (PA requests for non-preferred cytokine and CAM antagonist drugs must be submitted on paper.) |  |   |  |  |
|---|--|---|--|--|
| ,   | gonist drug(s) the member has taken continue documentation in Section V    | and provide specific details regarding the treatment I of this form.                |  |  |
|   | edical records must be submitted w<br>is medication use, and outline the i | vith the PA request to support the condition being member's current treatment plan. |  |  |
| 1. Drug Name  | Dose   | Dates Taken   |  |  |
| Reason for Discontinuation  |  |   |  |  |
|   |  |   |  |  |
| 2. Drug Name  | Dose   | Dates Taken   |  |  |
| Reason for Discontinuation  |  |   |  |  |
| 3. Drug Name<br>Reason for Discontinuation  |  | Dates Taken   |  |  |
|   |  |   |  |  |

19. Indicate the clinical reason(s) why the prescriber is requesting a non-preferred cytokine and CAM antagonist drug.

| SECTION IV – AUTHORIZED SIGNATURE |                 |  |  |
|-----------------------------------|-----------------|--|--|
| 20. SIGNATURE – Prescriber        | 21. Date Signed |  |  |
|                                   | Continued       |  |  |

# PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR PSORIASIS

F-11306 (01/2018)

| 23. Days' Supply Requested (Up to 365 Days) |
|---|
|   |
|   |
|   |
|   |

25. Date of Service (MM/DD/CCYY) (For STAT-PA requests, the date of service may be up to 31 days in the future or up to 14 days in the past.)

#### 26. Place of Service

#### 27. Assigned PA Number

| 28. Grant Date | 29. Expiration Date | 30. Number of Days Approved |
|----------------|---------------------|-----------------------------|
|                |                     |                             |

#### SECTION VI – ADDITIONAL INFORMATION

31. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the product requested may be included here.